4baseCare
PrivateLast Round
Series B
Jan 27, 2026
Total Funding Raised
$22.23M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
4baseCare operates in Healthcare & Life Sciences and is based in Bangalore. Its latest recorded funding round was a Series B round in January 2026.
4baseCare is a genomics and digital health company that develops innovative technologies aimed at revolutionizing precision oncology in Asia by creating a comprehensive, patient-focused ecosystem that supports pharmaceutical companies in delivering personalized cancer treatments for improved clinical outcomes.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Medical AI, Healthcare Analytics
Business Model
B2B2C
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
4baseCare Comparables
Compare 4baseCare with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lucence | 85% | |
| Gene Solutions | 83% | |
| Datar Cancer Genetics | 78% |
For institutional investors. Book with your work email.
4baseCare Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 27, 2026 | ||||
| Series A | Aug 12, 2024 | ||||
| Seed | Mar 11, 2021 | ||||
| Seed | May 20, 2020 | ||||
| Accelerator | Oct 21, 2019 | ||||
Grant | Jul 31, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
4baseCare Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Startup Karnataka | Seed |
| GrowX Ventures | Seed |
| First In | Seed |
| Season Two Ventures | Seed |
| Florintree Advisors | Series A |
| First In Ventures | Seed |
| Mount Judi Ventures | Series A, Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 62% MoM.
- Aug 1, 2026
Open roles increased to 36, 2.5x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesAug 17, 2026
4baseCare launches TARGT Indiegene(R) V2, a next-generation comprehensive genomic profiling test for cancer biomarker testing, on Aug 17th '26.
For institutional investors. Book with your work email.
4baseCare Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about 4baseCare's valuation, stock price, and market status.
Is 4baseCare a public or private company?
4baseCare is a private company.
What is the current stock price of 4baseCare?
4baseCare is a private company, so its shares have no public market price. Caplight tracks 4baseCare's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is 4baseCare worth (valuation)?
Valuation information for 4baseCare is not publicly available.
Can I buy 4baseCare stock?
4baseCare shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was 4baseCare's last funding round?
4baseCare's most recent funding round was Series B on January 27, 2026.
Who are the main investors in 4baseCare?
Key investors in 4baseCare include GrowX Ventures, First In, Florintree Advisors, Mount Judi Ventures, Illumina Accelerator.
Will 4baseCare IPO soon?
No public IPO plans have been announced for 4baseCare.
How can I track 4baseCare secondary market activity?
Caplight tracks bids, offers, and trades in 4baseCare's shares on secondary markets.